The fact that these recurrent mutations affect BRCA1 exon 11 may have therapeutic relevance because there is evidence that tumours that harbour BRCA1 exon 11 mutations can derive platinum and poly (ADP-ribose) polymerase (PARP) inhibitor resistance through generation of an exon 11-skipped hypomorphic isoform that partially restores BRCA1 function.20 The gene discussed is BRCA1; the disease is neoplasm.